

EXHIBIT E

True Supporting Letter (Left) side-by-side with forged Supporting Letter (Right)



Alpha-O Peptides, AG
Research and Development of
Nanobiotech-Pharmaceuticals

Prof. Dr. Peter Burkhard, CEO
Alpha-O Peptides
Lörracherstrasse 50
4125 Riehen
peter.burkhard@aopeptides.ch

Lbakhir BenMohamed, PhD.
Professor & Director
Cellular & Molecular Immunology
Laboratory
The Gavin Herbert Institute
Institute for Immunology
UC Irvine, School of Medicine
University of California Irvine

Riehen, August 31, 2018

Dear Dr. BenMohamed,

As you know, Alpha-O peptides owns valuable technology, intellectual property (US8575110, US8546337, US2014/0242104A1, EP3092245A1, and EP17157687.9) and proprietary information related to the design, construction, and bio-production of self-assembling protein nanoparticles (SAPNs). For this project of engineering ten pairs of CD4/CD8 T-cell epitopes into the SAPNs, Alpha-O Peptides has executed a separate written agreement to work exclusively with Sunomix Therapeutics and to transfer the technology for the bio-production of such SAPN-based HSV-vaccines from Alpha-O Peptides to Sunomix Therapeutics. Sunomix Therapeutics will use the validated bio-production protocol provided by Alpha-O to generate similar HSV-SAPN constructs. Sunomix has in the meantime acquired the know-how of the production of SAPN-based vaccines based on previous collaborations with Alpha-O Peptides. Sunomix Therapeutics will be responsible to deliver at least 2 mg of pure SAPN-protein of the constructs to your laboratory at the University of California, Irvine, to be used for the immunization experiments of the project described in the NIH-STTR ocular herpes vaccine grant proposal. The experiments you propose to test the SAPN-based ocular herpes vaccines in "humanized" HLA transgenic mice are very innovative. I do not know of anyone conducting detailed studies of SAPN-based ocular herpes vaccine. Based on your recent publications, it seems quite possible that T cells from HSV positive symptomatic versus asymptomatic individuals recognize different sets of HSV antigens. Therefore, to develop a better herpes vaccine, I think it is crucial to answer the questions you are raising in your proposal.

Yours sincerely,

Peter Burkhard

CEO, Alpha-O Peptides AG



Alpha-O Peptides, AG
Research and Development of
Nanobiotech-Pharmaceuticals

Prof. Dr. Peter Burkhard, CEO
Alpha-O Peptides
Lörracherstrasse 50
4125 Riehen
peter.burkhard@aopeptides.ch

Lbakhir BenMohamed, PhD.
Professor & Director
Cellular & Molecular Immunology
Laboratory
The Gavin Herbert Institute
Institute for Immunology
UC Irvine, School of Medicine
University of California Irvine

Riehen, December 10, 2018

Dear Dr. BenMohamed,

As you know, Alpha-O peptides owns valuable technology, intellectual property (US8575110, US8546337, US2014/0242104A1, EP3092245A1, and EP17157687.9) and proprietary information related to the design, construction, and bio-production of self-assembling protein nanoparticles (SAPNs). For this project of engineering ten pairs of CD4/CD8 T-cell epitopes into the SAPNs, Alpha-O Peptides has executed a separate written agreement to work exclusively with Sunomix Therapeutics and to transfer the technology for the bio-production of such SAPN-based HSV-vaccines from Alpha-O Peptides to Sunomix Therapeutics. Sunomix Therapeutics will use the validated bio-production protocol provided by Alpha-O to generate similar HSV-SAPN constructs. Sunomix has in the meantime acquired the know-how of the production of SAPN-based vaccines based on previous collaborations with Alpha-O Peptides. Sunomix Therapeutics will be responsible to deliver at least 2 mg of pure SAPN-protein of the constructs to your laboratory at the University of California, Irvine, to be used for the immunization experiments of the project described in the ocular herpes vaccine grant proposal.

The experiments you propose to test the SAPN-based ocular herpes vaccines in "humanized" HLA transgenic mice are very innovative. I do not know of anyone conducting detailed studies of SAPN-based ocular herpes vaccine. Based on your recent publications, it seems quite possible that T cells from HSV positive symptomatic versus asymptomatic individuals recognize different sets of HSV antigens. Therefore, to develop a better herpes vaccine, I think it is crucial to answer the questions you are raising in your proposal.

Yours sincerely,

Peter Burkhard

CEO, Alpha-O Peptides AG